1. Home
  2. GROW vs ATNM Comparison

GROW vs ATNM Comparison

Compare GROW & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Global Investors Inc.

GROW

U.S. Global Investors Inc.

SELL

Current Price

$2.83

Market Cap

32.7M

Sector

Finance

ML Signal

SELL

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

SELL

Current Price

$0.97

Market Cap

31.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GROW
ATNM
Founded
1968
2000
Country
United States
United States
Employees
N/A
25
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
31.4M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
GROW
ATNM
Price
$2.83
$0.97
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $3.60
AVG Volume (30 Days)
10.9K
★ 98.9K
Earning Date
11-11-2026
11-13-2026
Dividend Yield
★ 3.15%
N/A
EPS Growth
★ 900.00
14.17
EPS
0.24
★ 0.71
Revenue
★ $14,399,000.00
$90,000.00
Revenue This Year
N/A
$19,344.45
Revenue Next Year
N/A
N/A
P/E Ratio
$11.92
★ $1.41
Revenue Growth
★ 32.77
11.11
52 Week Low
$2.23
$0.74
52 Week High
$3.65
$1.74

Technical Indicators

Market Signals
Indicator
GROW
ATNM
Relative Strength Index (RSI) 29.45 34.56
Support Level $2.45 $0.88
Resistance Level $2.75 $1.13
Average True Range (ATR) 0.08 0.07
MACD -0.01 -0.03
Stochastic Oscillator 10.53 1.27

Price Performance

Historical Comparison
GROW
ATNM

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: